tiprankstipranks
Advertisement
Advertisement

KLRS Stock Latest News

Kalaris Therapeutics initiated with an Overweight at Morgan Stanley
The FlyKalaris Therapeutics initiated with an Overweight at Morgan Stanley
20d ago
KLRS
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
PremiumCompany Announcements
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
25d ago
8K
KLRS
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
PremiumRatings
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
2M ago
KLRS
Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
PremiumThe Fly
Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
2M ago
KLRS
Kalaris Therapeutics sees cash runway into 4Q27
PremiumThe Fly
Kalaris Therapeutics sees cash runway into 4Q27
2M ago
KLRS
Kalaris Updates TH103 Strategy and Highlights Cash Runway
PremiumCompany AnnouncementsKalaris Updates TH103 Strategy and Highlights Cash Runway
2M ago
8K
KLRS
Vizsla, Coty, Kalaris, Annexon, Brown & Brown Trending
Premium
Weekend Updates
Vizsla, Coty, Kalaris, Annexon, Brown & Brown Trending
4M ago
BRO
ANNX
Kalaris Therapeutics initiated with a Buy at Chardan
Premium
The Fly
Kalaris Therapeutics initiated with a Buy at Chardan
4M ago
KLRS
Early Clinical Strength and Durability of TH103 Underpin Buy Rating on Kalaris Therapeutics
PremiumRatings
Early Clinical Strength and Durability of TH103 Underpin Buy Rating on Kalaris Therapeutics
4M ago
KLRS
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing
PremiumCompany Announcements
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing
5M ago
8K
KLRS
Kalaris Therapeutics price target raised to $26 from $20 at Citizens
PremiumThe Fly
Kalaris Therapeutics price target raised to $26 from $20 at Citizens
5M ago
KLRS
Kalaris Therapeutics announces $50M private placement
PremiumThe Fly
Kalaris Therapeutics announces $50M private placement
5M ago
KLRS
Kalaris Therapeutics expects cash, equivalents to fund operations into 3Q27
PremiumThe FlyKalaris Therapeutics expects cash, equivalents to fund operations into 3Q27
5M ago
KLRS
Kalaris Therapeutics Announces Positive Phase 1a Trial Data
Premium
Company Announcements
Kalaris Therapeutics Announces Positive Phase 1a Trial Data
5M ago
8K
KLRS
Kalaris Therapeutics announces initial data from TH103 trial
Premium
The Fly
Kalaris Therapeutics announces initial data from TH103 trial
5M ago
KLRS
Kalaris Therapeutics Reports Q3 2025 Financial Progress
PremiumCompany Announcements
Kalaris Therapeutics Reports Q3 2025 Financial Progress
6M ago
KLRS
Positive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments
PremiumRatings
Positive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments
6M ago
KLRS
Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)
PremiumThe Fly
Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)
6M ago
KLRS
Kalaris Therapeutics Appoints New CFO Matthew Gall
PremiumCompany Announcements
Kalaris Therapeutics Appoints New CFO Matthew Gall
6M ago
8K
KLRS
Kalaris Therapeutics appoints Gall as Chief Financial Officer
PremiumThe FlyKalaris Therapeutics appoints Gall as Chief Financial Officer
6M ago
KLRS
Kalaris Therapeutics initiated with an Outperform at Citizens JMP
Premium
The Fly
Kalaris Therapeutics initiated with an Outperform at Citizens JMP
6M ago
KLRS
Optimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD
Premium
Ratings
Optimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD
8M ago
KLRS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >